As many as four percent of the world’s population lives with an autoimmune disease, in which the immune system fails to distinguish between ‘self’ and ‘non-self’ and mistakenly attacks the body, ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) results in disability through immune-mediated nerve injury, which can lead to irreversible deficits after the inflammatory component of CIDP is ...
Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...
Identification and correct diagnosis of the chronic acquired demyelinating polyneuropathies is important because they are immune-mediated and, therefore, amenable to treatment Early diagnosis and ...
Discovery of the antigenic targets associated with nerve-specific autoimmune diseases is a crucial step in understanding their pathogenesis The identification of highly disease-specific autoantibodies ...
Chronic Inflammatory Demyelinating Polyneuropathy Companies such as Takeda, Sanofi, Johnson & Johnson Services, Immunovant, UCB S.A., GeNeuro, Nanjing IASO ...
ImmuPharma receives confirmation of pre-IND meeting date with FDA for a Phase 2/3 adaptive study of P140 in CIDP ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback